Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance

Aceto, 2014, Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis, Cell, 158, 1110, 10.1016/j.cell.2014.07.013 Alexandrov, 2013, Signatures of mutational processes in human cancer, Nature, 500, 415, 10.1038/nature12477 Alfarouk, 2013, Riparian ecosystems in human cancers, Evol. Appl., 6, 46, 10.1111/eva.12015 Almendro, 2014, Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity, Cell Rep., 6, 514, 10.1016/j.celrep.2013.12.041 Anagnostou, 2019, Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer, Cancer Res., 79, 1214, 10.1158/0008-5472.CAN-18-1127 Anagnostou, 2017, Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer, Cancer Discov., 7, 264, 10.1158/2159-8290.CD-16-0828 Andor, 2016, Pan-cancer analysis of the extent and consequences of intratumor heterogeneity, Nat. Med., 22, 105, 10.1038/nm.3984 Angelo, 2014, Multiplexed ion beam imaging of human breast tumors, Nat. Med., 20, 436, 10.1038/nm.3488 Angelova, 2018, Evolution of metastases in space and time under immune selection, Cell, 175, 751, 10.1016/j.cell.2018.09.018 Bakhoum, 2018, The multifaceted role of chromosomal instability in cancer and its microenvironment, Cell, 174, 1347, 10.1016/j.cell.2018.08.027 Beckman, 2006, Efficiency of carcinogenesis with and without a mutator mutation, Proc. Natl. Acad. Sci. U S A, 103, 14140, 10.1073/pnas.0606271103 Bielski, 2018, Genome doubling shapes the evolution and prognosis of advanced cancers, Nat. Genet., 50, 1189, 10.1038/s41588-018-0165-1 Bozic, 2013, Evolutionary dynamics of cancer in response to targeted combination therapy, eLife, 2, e00747, 10.7554/eLife.00747 Brocks, 2014, Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer, Cell Rep., 8, 798, 10.1016/j.celrep.2014.06.053 Bussard, 2012, Human breast cancer cells are redirected to mammary epithelial cells upon interaction with the regenerating mammary gland microenvironment in-vivo, PLoS One, 7, e49221, 10.1371/journal.pone.0049221 Carmeliet, 2000, Angiogenesis in cancer and other diseases, Nature, 407, 249, 10.1038/35025220 Chabon, 2016, Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients, Nat. Commun., 7, 11815, 10.1038/ncomms11815 Chakrabarti, 2017, Pharmacokinetics and drug interactions determine optimum combination strategies in computational models of cancer evolution, Cancer Res., 77, 3908, 10.1158/0008-5472.CAN-16-2871 Colotta, 2009, Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability, Carcinogenesis, 30, 1073, 10.1093/carcin/bgp127 Dawson, 2013, Analysis of circulating tumor DNA to monitor metastatic breast cancer, N. Engl. J. Med., 368, 1199, 10.1056/NEJMoa1213261 deCarvalho, 2018, Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma, Nat. Genet., 50, 708, 10.1038/s41588-018-0105-0 Dewhurst, 2014, Tolerance of whole- genome doubling propagates chromosomal instability and accelerates cancer genome evolution, Cancer Discov., 4, 175, 10.1158/2159-8290.CD-13-0285 Duelli, 2007, A virus causes cancer by inducing massive chromosomal instability through cell fusion, Curr. Biol., 17, 431, 10.1016/j.cub.2007.01.049 Duncan, 2010, The ploidy conveyor of mature hepatocytes as a source of genetic variation, Nature, 467, 707, 10.1038/nature09414 Dunn, 2004, The three Es of cancer immunoediting, Annu. Rev. Immunol., 22, 329, 10.1146/annurev.immunol.22.012703.104803 Estrella, 2013, Acidity generated by the tumor microenvironment drives local invasion, Cancer Res., 73, 1524, 10.1158/0008-5472.CAN-12-2796 Fais, 2018, Cell-in-cell phenomena in cancer, Nat. Rev. Cancer, 18, 758, 10.1038/s41568-018-0073-9 Fane, 2019, How the ageing microenvironment influences tumour progression, Nat. Rev. Cancer, 20, 89, 10.1038/s41568-019-0222-9 Feinberg, 2007, Phenotypic plasticity and the epigenetics of human disease, Nature, 447, 433, 10.1038/nature05919 Filho, 2019, HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: results from a prospective clinical trial, J. Clin. Oncol., 37, 502, 10.1200/JCO.2019.37.15_suppl.502 Flavahan, 2017, Epigenetic plasticity and the hallmarks of cancer, Science, 357, 10.1126/science.aal2380 Foo, 2014, Evolution of acquired resistance to anti-cancer therapy, J. Theor. Biol., 355, 10, 10.1016/j.jtbi.2014.02.025 Fox, 2013, Do mutator mutations fuel tumorigenesis?, Cancer Metastasis Rev., 32, 353, 10.1007/s10555-013-9426-8 Gaiti, 2019, Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia, Nature, 569, 576, 10.1038/s41586-019-1198-z Gallaher, 2018, Spatial heterogeneity and evolutionary dynamics modulate time to recurrence in continuous and adaptive cancer therapies, Cancer Res., 78, 2127, 10.1158/0008-5472.CAN-17-2649 Gast, 2018, Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival, Sci. Adv., 4, eaat7828, 10.1126/sciadv.aat7828 Gatenby, 2008, A microenvironmental model of carcinogenesis, Nat. Rev. Cancer, 8, 56, 10.1038/nrc2255 Gejman, 2018, Rejection of immunogenic tumor clones is limited by clonal fraction, eLife, 7, 10.7554/eLife.41090 Gerlinger, 2012, Intratumor heterogeneity and branched evolution revealed by multiregion sequencing, N. Engl. J. Med., 366, 883, 10.1056/NEJMoa1113205 Gillies, 2018, Eco-evolutionary causes and consequences of temporal changes in intratumoural blood flow, Nat. Rev. Cancer, 18, 576, 10.1038/s41568-018-0030-7 Gillies, 2012, Evolutionary dynamics of carcinogenesis and why targeted therapy does not work, Nat. Rev. Cancer, 12, 487, 10.1038/nrc3298 Godek, 2016, Chromosomal instability affects the tumorigenicity of glioblastoma tumor-initiating cells, Cancer Discov., 6, 532, 10.1158/2159-8290.CD-15-1154 Goldman, 2015, Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition, Nat. Commun., 6, 6139, 10.1038/ncomms7139 Granja, 2019, Single-cell multiomic analysis identifies regulatory programs in mixed-phenotype acute leukemia, Nat. Biotechnol., 37, 1458, 10.1038/s41587-019-0332-7 Grivennikov, 2010, Immunity, inflammation, and cancer, Cell, 140, 883, 10.1016/j.cell.2010.01.025 Gruosso, 2019, Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers, J. Clin. Invest., 129, 1785, 10.1172/JCI96313 Hangauer, 2017, Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition, Nature, 551, 247, 10.1038/nature24297 Hata, 2016, Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition, Nat. Med., 22, 262, 10.1038/nm.4040 Havel, 2019, The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy, Nat. Rev. Cancer, 19, 133, 10.1038/s41568-019-0116-x Hinohara, 2019, Intratumoral heterogeneity: more than just mutations, Trends Cell Biol., 29, 569, 10.1016/j.tcb.2019.03.003 Hinohara, 2018, KDM5 histone demethylase activity links cellular transcriptomic heterogeneity to therapeutic resistance, Cancer Cell, 34, 939, 10.1016/j.ccell.2018.10.014 Hirata, 2015, Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin beta1/FAK signaling, Cancer Cell, 27, 574, 10.1016/j.ccell.2015.03.008 Hirata, 2017, Tumor microenvironment and differential responses to therapy, Cold Spring Harb Perspect. Med., 7, 10.1101/cshperspect.a026781 Hoefflin, 2016, Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity, Nat. Commun., 7, 10.1038/ncomms11845 Holohan, 2013, Cancer drug resistance: an evolving paradigm, Nat. Rev. Cancer, 13, 714, 10.1038/nrc3599 Hong, 2019, Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy, Nat. Commun., 10, 3840, 10.1038/s41467-019-11721-9 Jacobsen, 2006, Spontaneous fusion with, and transformation of mouse stroma by, malignant human breast cancer epithelium, Cancer Res., 66, 8274, 10.1158/0008-5472.CAN-06-1456 Jain, 2014, Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia, Cancer Cell, 26, 605, 10.1016/j.ccell.2014.10.006 Jamal-Hanjani, 2017, Tracking the evolution of non-small-cell lung cancer, N. Engl. J. Med., 376, 2109, 10.1056/NEJMoa1616288 Janiszewska, 2015, In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer, Nat. Genet., 47, 1212, 10.1038/ng.3391 Jenkinson, 2017, Potential energy landscapes identify the information-theoretic nature of the epigenome, Nat. Genet., 49, 719, 10.1038/ng.3811 Jimenez-Sanchez, 2017, Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient, Cell, 170, 927, 10.1016/j.cell.2017.07.025 Joshi, 2019, Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer, Nat. Med., 25, 1549, 10.1038/s41591-019-0592-2 Kalbasi, 2019, Tumour-intrinsic resistance to immune checkpoint blockade, Nat. Rev. Immunol., 20, 25, 10.1038/s41577-019-0218-4 Kandoth, 2013, Mutational landscape and significance across 12 major cancer types, Nature, 502, 333, 10.1038/nature12634 Karnoub, 2007, Mesenchymal stem cells within tumour stroma promote breast cancer metastasis, Nature, 449, 557, 10.1038/nature06188 Keren, 2018, A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging, Cell, 174, 1373, 10.1016/j.cell.2018.08.039 Kersten, 2017, Genetically engineered mouse models in oncology research and cancer medicine, EMBO Mol. Med., 9, 137, 10.15252/emmm.201606857 Khan, 2018, Longitudinal liquid biopsy and mathematical modeling of clonal evolution forecast time to treatment failure in the PROSPECT-C phase II colorectal cancer clinical trial, Cancer Discov., 8, 1270, 10.1158/2159-8290.CD-17-0891 Knoechel, 2014, An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia, Nat. Genet., 46, 364, 10.1038/ng.2913 Korenchan, 2019, Spatiotemporal pH heterogeneity as a promoter of cancer progression and therapeutic resistance, Cancers (Basel), 11, 10.3390/cancers11071026 Korkaya, 2011, Regulation of cancer stem cells by cytokine networks: attacking cancer's inflammatory roots, Clin. Cancer Res., 17, 6125, 10.1158/1078-0432.CCR-10-2743 LaBerge, 2017, A melanoma lymph node metastasis with a donor-patient hybrid genome following bone marrow transplantation: a second case of leucocyte-tumor cell hybridization in cancer metastasis, PLoS One, 12, e0168581, 10.1371/journal.pone.0168581 Landau, 2014, Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia, Cancer Cell, 26, 813, 10.1016/j.ccell.2014.10.012 Lazova, 2013, A melanoma brain metastasis with a donor-patient hybrid genome following bone marrow transplantation: first evidence for fusion in human cancer, PLoS One, 8, e66731, 10.1371/journal.pone.0066731 Leder, 2014, Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules, Cell, 156, 603, 10.1016/j.cell.2013.12.029 Lengauer, 1997, Genetic instability in colorectal cancers, Nature, 386, 623, 10.1038/386623a0 Li, 2009, Cancer-causing karyotypes: chromosomal equilibria between destabilizing aneuploidy and stabilizing selection for oncogenic function, Cancer Genet. Cytogenet., 188, 1, 10.1016/j.cancergencyto.2008.08.016 Liau, 2017, Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance, Cell Stem Cell, 20, 233, 10.1016/j.stem.2016.11.003 Lin, 2015, Highly multiplexed imaging of single cells using a high-throughput cyclic immunofluorescence method, Nat. Commun., 6, 8390, 10.1038/ncomms9390 Lloyd, 2016, Darwinian dynamics of intratumoral heterogeneity: not solely random mutations but also variable environmental selection forces, Cancer Res., 76, 3136, 10.1158/0008-5472.CAN-15-2962 Lovly, 2014, Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies, Clin. Cancer Res., 20, 2249, 10.1158/1078-0432.CCR-13-1610 Lu, 2009, Efficient acquisition of dual metastasis organotropism to bone and lung through stable spontaneous fusion between MDA-MB-231 variants, Proc. Natl. Acad. Sci. U S A, 106, 9385, 10.1073/pnas.0900108106 Mann, 2016, Analyzing tumor heterogeneity and driver genes in single myeloid leukemia cells with SBCapSeq, Nat. Biotechnol., 34, 962, 10.1038/nbt.3637 Mariathasan, 2018, TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells, Nature, 554, 544, 10.1038/nature25501 Marusyk, 2012, Intra-tumour heterogeneity: a looking glass for cancer?, Nat. Rev. Cancer, 12, 323, 10.1038/nrc3261 Marusyk, 2016, Spatial proximity to fibroblasts impacts molecular features and therapeutic sensitivity of breast cancer cells influencing clinical outcomes, Cancer Res., 76, 6495, 10.1158/0008-5472.CAN-16-1457 Mazor, 2015, DNA methylation and somatic mutations converge on the cell cycle and define similar evolutionary histories in brain tumors, Cancer Cell, 28, 307, 10.1016/j.ccell.2015.07.012 Mazor, 2016, Intratumoral heterogeneity of the epigenome, Cancer Cell, 29, 440, 10.1016/j.ccell.2016.03.009 McGranahan, 2016, Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade, Science, 351, 1463, 10.1126/science.aaf1490 McGranahan, 2017, Clonal heterogeneity and tumor evolution: past, present, and the future, Cell, 168, 613, 10.1016/j.cell.2017.01.018 Meads, 2009, Environment-mediated drug resistance: a major contributor to minimal residual disease, Nat. Rev. Cancer, 9, 665, 10.1038/nrc2714 Merlo, 2006, Cancer as an evolutionary and ecological process, Nat. Rev. Cancer, 6, 924, 10.1038/nrc2013 Merlo, 2010, A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma, Cancer Prev. Res., 3, 1388, 10.1158/1940-6207.CAPR-10-0108 Miller, 2019, Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid, Nature, 565, 654, 10.1038/s41586-019-0882-3 Milo, 2018, The immune system profoundly restricts intratumor genetic heterogeneity, Sci. Immunol., 3, 10.1126/sciimmunol.aat1435 Miroshnychenko, 2020, Spontaneous cell fusions as a mechanism of parasexual recombination in tumor cell populations, BioRxiv Misale, 2012, Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer, Nature, 486, 532, 10.1038/nature11156 Modi, 2019, Trastuzumab deruxtecan in previously treated HER2-positive breast cancer, N. Engl. J. Med., 382, 610, 10.1056/NEJMoa1914510 Mohlin, 2017, Hypoxia, pseudohypoxia and cellular differentiation, Exp. Cell Res., 356, 192, 10.1016/j.yexcr.2017.03.007 Morris, 2016, Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival, Oncotarget, 7, 10051, 10.18632/oncotarget.7067 Naba, 2012, The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices, Mol. Cell Proteomics, 11, 10.1074/mcp.M111.014647 Nathanson, 2014, Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA, Science, 343, 72, 10.1126/science.1241328 Neftel, 2019, An integrative model of cellular states, plasticity, and genetics for glioblastoma, Cell, 178, 835, 10.1016/j.cell.2019.06.024 Niknafs, 2019, Characterization of genetic subclonal evolution in pancreatic cancer mouse models, Nat. Commun., 10, 5435, 10.1038/s41467-019-13100-w Noman, 2015, Hypoxia: a key player in antitumor immune response. A review in the theme: cellular responses to hypoxia, Am. J. Physiol. Cell Physiol., 309, C569, 10.1152/ajpcell.00207.2015 Patel, 2014, Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma, Science, 344, 1396, 10.1126/science.1254257 Pilon-Thomas, 2016, Neutralization of tumor acidity improves antitumor responses to immunotherapy, Cancer Res., 76, 1381, 10.1158/0008-5472.CAN-15-1743 Piotrowska, 2015, Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor, Cancer Discov., 5, 713, 10.1158/2159-8290.CD-15-0399 Pisco, 2015, Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: 'what does not kill me strengthens me', Br. J. Cancer, 112, 1725, 10.1038/bjc.2015.146 Ramirez, 2016, Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells, Nat. Commun., 7, 10690, 10.1038/ncomms10690 Reuben, 2017, TCR repertoire intratumor heterogeneity in localized lung adenocarcinomas: an association with predicted neoantigen heterogeneity and postsurgical recurrence, Cancer Discov., 7, 1088, 10.1158/2159-8290.CD-17-0256 Ribas, 2018, Cancer immunotherapy using checkpoint blockade, Science, 359, 1350, 10.1126/science.aar4060 Risom, 2018, Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer, Nat. Commun., 9, 3815, 10.1038/s41467-018-05729-w Robertson-Tessi, 2015, Impact of metabolic heterogeneity on tumor growth, invasion, and treatment outcomes, Cancer Res., 75, 1567, 10.1158/0008-5472.CAN-14-1428 Rockne, 2019, Introduction to mathematical oncology, JCO Clin Cancer Inform, 3, 1, 10.1200/CCI.19.00010 Roe, 2017, Enhancer reprogramming promotes pancreatic cancer metastasis, Cell, 170, 875, 10.1016/j.cell.2017.07.007 Roesch, 2013, Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells, Cancer Cell, 23, 811, 10.1016/j.ccr.2013.05.003 Rosenthal, 2019, Neoantigen-directed immune escape in lung cancer evolution, Nature, 567, 479, 10.1038/s41586-019-1032-7 Rossi, 2019, Promises and pitfalls of using liquid biopsy for precision medicine, Cancer Res., 79, 2798, 10.1158/0008-5472.CAN-18-3402 Russo, 2019, Adaptive mutability of colorectal cancers in response to targeted therapies, Science, 366, 1473, 10.1126/science.aav4474 Rye, 2018, Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors, Mol. Oncol., 12, 1838, 10.1002/1878-0261.12375 Senovilla, 2012, An immunosurveillance mechanism controls cancer cell ploidy, Science, 337, 1678, 10.1126/science.1224922 Seth, 2019, Pre-existing functional heterogeneity of tumorigenic compartment as the origin of chemoresistance in pancreatic tumors, Cell Rep., 26, 1518, 10.1016/j.celrep.2019.01.048 Shaffer, 2017, Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance, Nature, 546, 431, 10.1038/nature22794 Sharma, 2010, A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations, Cell, 141, 69, 10.1016/j.cell.2010.02.027 Shipitsin, 2007, Molecular definition of breast tumor heterogeneity, Cancer Cell, 11, 259, 10.1016/j.ccr.2007.01.013 Shu, 2016, Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer, Nature, 529, 413, 10.1038/nature16508 Singh, 2010, EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer, Oncogene, 29, 4741, 10.1038/onc.2010.215 Siravegna, 2015, Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients, Nat. Med., 21, 827, 10.1038/nm0715-827b Spitzer, 2016, Mass cytometry: single cells, many features, Cell, 165, 780, 10.1016/j.cell.2016.04.019 Stacker, 2014, Lymphangiogenesis and lymphatic vessel remodelling in cancer, Nat. Rev. Cancer, 14, 159, 10.1038/nrc3677 Storchova, 2004, From polyploidy to aneuploidy, genome instability and cancer, Nat. Rev. Mol. Cell Biol., 5, 45, 10.1038/nrm1276 Tang, 2013, Gene copy-number alterations: a cost-benefit analysis, Cell, 152, 394, 10.1016/j.cell.2012.11.043 Thrane, 2018, Spatially resolved transcriptomics enables dissection of genetic heterogeneity in stage III cutaneous malignant melanoma, Cancer Res., 78, 5970, 10.1158/0008-5472.CAN-18-0747 Tomasetti, 2015, Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions, Science, 347, 78, 10.1126/science.1260825 Tomlinson, 1996, The mutation rate and cancer, Proc. Natl. Acad. Sci. U S A, 93, 14800, 10.1073/pnas.93.25.14800 Turner, 2017, Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity, Nature, 543, 122, 10.1038/nature21356 Vander Velde, 2019, Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures, bioRxiv, 504837 Verhaak, 2019, Extrachromosomal oncogene amplification in tumour pathogenesis and evolution, Nat. Rev. Cancer, 19, 283, 10.1038/s41568-019-0128-6 Vogelstein, 2004, Cancer genes and the pathways they control, Nat. Med., 10, 789, 10.1038/nm1087 Wilson, 2012, Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors, Nature, 487, 505, 10.1038/nature11249 Wodarz, 2005, Emergence and prevention of resistance against small molecule inhibitors, Semin. Cancer Biol., 15, 506, 10.1016/j.semcancer.2005.07.002 Wolf, 2019, UVB-induced tumor heterogeneity diminishes immune response in melanoma, Cell, 179, 219, 10.1016/j.cell.2019.08.032 Yates, 2015, Subclonal diversification of primary breast cancer revealed by multiregion sequencing, Nat. Med., 21, 751, 10.1038/nm.3886 Yuan, 2016, Spatial heterogeneity in the tumor microenvironment, Cold Spring Harb Perspect. Med., 6, 10.1101/cshperspect.a026583 Zhang, 2018, Interfaces of malignant and immunologic clonal dynamics in ovarian cancer, Cell, 173, 1755, 10.1016/j.cell.2018.03.073 Zhang, 2017, Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer, Nat Commun., 8, 1816, 10.1038/s41467-017-01968-5 Zhang, 2014, Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing, Science, 346, 256, 10.1126/science.1256930 Zhang, 2009, Targeting cancer with small molecule kinase inhibitors, Nat. Rev. Cancer, 9, 28, 10.1038/nrc2559 Zhang, 2018, Somatic mutagenesis in mammals and its implications for human disease and aging, Annu. Rev. Genet., 52, 397, 10.1146/annurev-genet-120417-031501 Zhang, 2015, Selective advantages of a parasexual cycle for the yeast Candida albicans, Genetics, 200, 1117, 10.1534/genetics.115.177170